8-K Announcements
6Material company update
May 13, 2026·SEC
Material company update
Apr 21, 2026·SEC
Material company update
Mar 25, 2026·SEC
Journey Medical Corporation(DERM)Earnings, Financials & Key Ratios
DERM•NASDAQ
$6.75
Price updated Jul 7, 2026
AboutJourney Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.Show more
- Revenue$62M+10.2%
- EBITDA-$4M+62.3%
- Net Income-$11M+22.1%
- EPS (Diluted)-0.47+34.7%
- Gross Margin59.29%-5.6%
- EBITDA Margin-6.19%+65.8%
- Operating Margin-13.21%+45.8%
- Net Margin-18.48%+29.3%
- ROE-44.03%+39.3%
DERM Price & Volume
Journey Medical Corporation (DERM) stock price & volume — 10-year historical chart
Loading chart...
Volatile Commercial Scaling Masks Persistent Operational Deficits
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Limited liquidity and burn
Key Thesis Takeaways
- Journey Medical Corporation faces a challenging path to profitability as its commercial infrastructure struggles to scale, evidenced by persistent negative operating margins that reached -77.4% in 2024Q1.
- While the company exhibits intermittent revenue growth, such as the 21.5% expansion in 2026Q1, the reliance on acquired assets and significant stock-based compensation, which peaked at $1.7M in 2024Q2, complicates the assessment of long-term value.
- Investors should monitor the company's limited liquidity, as the current ratio remains narrow between 1.21 and 1.79, suggesting that the business model remains highly sensitive to operational shocks and inventory management volatility.
Verdict Logic
the company's inability to maintain consistent profitability is highlighted by a TTM P/E of -14.09 and a history of operating expenses that consistently outpace gross profit.
DERM Growth Metrics
Journey Medical Corporation (DERM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years23.82%
5 Years6.79%
3 Years-5.66%
TTM15%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-15.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM6.33%
Return on Capital
10 Years-35.21%
5 Years-44.33%
3 Years-18.61%
Last Year-15.99%
DERM Recent Earnings
Journey Medical Corporation (DERM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 5/12 qtrs (42%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.08-14.3%
$0.07
Rev
$16M+3.2%
$15M
Q2 2026
Mar 25, 2026Metric
Actual
Est
EPS
$0.04+33.3%
$0.06
Rev
$16M-14.7%
$19M
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$0.09-12.5%
$0.08
Rev
$18M-6.5%
$19M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.16-128.6%
$0.07
Rev
$15M-20.6%
$19M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.08vs $0.07-14.3% | $16Mvs $15M+3.2% |
| Q2 2026 | Mar 25, 2026 | $0.04vs $0.06+33.3% | $16Mvs $19M-14.7% |
| Q4 2025 | Nov 12, 2025 | $0.09vs $0.08-12.5% | $18Mvs $19M-6.5% |
| Q3 2025 | Aug 12, 2025 | $0.16vs $0.07-128.6% | $15Mvs $19M-20.6% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Journey Medical Corporation (DERM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.75 | $185.63M | -14.35 | 10.2% | -18.48% | -44.03% | — | |
| $1.11 | $143.86M | -6.94 | -10.02% | -2.03% | -9.41% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — | |
| $17.72 | $2.02B | -14.52 | 8.28% | -25.66% | -50.82% | — | |
| $161.55 | $11.34B | 46.42 | 30.73% | 10.44% | 21.38% | — | |
| $0.67 | $28.65M | -1.08 | 13.77% | -4726.21% | -69.57% | — |
Compare DERM vs Peers
Journey Medical Corporation (DERM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
DERM SEC Filings & Documents
Journey Medical Corporation (DERM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when DERM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DERM Frequently Asked Questions
Journey Medical Corporation (DERM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Journey Medical Corporation's revenue?
Journey Medical Corporation (DERM) reported $64.7M in revenue for fiscal year 2025. This represents a 786% increase from $7.3M in 2014.
How fast is Journey Medical Corporation growing?
Journey Medical Corporation (DERM) grew revenue by 10.2% over the past year. This is steady growth.
Is DERM profitable?
Journey Medical Corporation (DERM) reported a net loss of $9.6M for fiscal year 2025.
Dividend & Returns
What is DERM's return on equity?
Journey Medical Corporation (DERM) has a return on equity (ROE) of -44.0%. Negative ROE indicates the company is unprofitable.
What is Journey Medical Corporation's free cash flow?
Journey Medical Corporation (DERM) had negative free cash flow of $6.8M in fiscal year 2025, likely due to heavy capital investments.